Jounce Therapeutics, Inc.
JNCE · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $57,360 | $416,924 | $247,982 | $288,788 |
| - Cash | $150,572 | $95,529 | $147,493 | $53,241 |
| + Debt | $10,020 | $13,688 | $16,889 | $19,790 |
| Enterprise Value | -$83,192 | $335,083 | $117,378 | $255,337 |
| Revenue | $82,000 | $26,907 | $62,339 | $147,872 |
| % Growth | 204.8% | -56.8% | -57.8% | – |
| Gross Profit | $82,000 | $26,907 | $62,339 | $147,872 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$50,155 | -$91,056 | -$45,117 | $52,817 |
| % Margin | -61.2% | -338.4% | -72.4% | 35.7% |
| Net Income | -$50,919 | -$90,872 | -$43,842 | $56,823 |
| % Margin | -62.1% | -337.7% | -70.3% | 38.4% |
| EPS Diluted | -0.99 | -1.82 | -1.24 | 1.66 |
| % Growth | 45.6% | -46.8% | -174.7% | – |
| Operating Cash Flow | -$28,877 | -$83,494 | -$27,788 | -$30,129 |
| Capital Expenditures | -$919 | -$373 | -$94 | -$985 |
| Free Cash Flow | -$29,796 | -$83,867 | -$27,882 | -$31,114 |